Akebia Therapeutics (AKBA) Revenue (2017 - 2025)
Historic Revenue for Akebia Therapeutics (AKBA) over the last 9 years, with Q3 2025 value amounting to $58.8 million.
- Akebia Therapeutics' Revenue rose 5701.08% to $58.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $225.1 million, marking a year-over-year increase of 162652.6%. This contributed to the annual value of $160.2 million for FY2024, which is 150180.0% up from last year.
- Akebia Therapeutics' Revenue amounted to $58.8 million in Q3 2025, which was up 5701.08% from $62.5 million recorded in Q2 2025.
- Over the past 5 years, Akebia Therapeutics' Revenue peaked at $126.4 million during Q2 2022, and registered a low of -$128.4 million during Q4 2023.
- Over the past 5 years, Akebia Therapeutics' median Revenue value was $48.8 million (recorded in 2021), while the average stood at $43.8 million.
- Its Revenue has fluctuated over the past 5 years, first skyrocketed by 22504.0% in 2021, then crashed by 33023.02% in 2023.
- Akebia Therapeutics' Revenue (Quarter) stood at $57.7 million in 2021, then dropped by 3.29% to $55.8 million in 2022, then tumbled by 330.23% to -$128.4 million in 2023, then soared by 136.21% to $46.5 million in 2024, then rose by 26.39% to $58.8 million in 2025.
- Its last three reported values are $58.8 million in Q3 2025, $62.5 million for Q2 2025, and $57.3 million during Q1 2025.